NCT06344208Recruiting
Predicting Toxicity in Elderly Patients With Head and Neck Cancer
Predicting Toxicity in Elderly Patients With Head and Neck Cancer: Validating a Disease-oriented Toxicity Predictive Tool and Integrating it With Available Screening Tools for Better Outcomes
Source: ClinicalTrials.gov · Last updated 24 Mar 2026
Brief summary (registry, in English)
Predicting toxicity in elderly patients with head and neck cancer: validating a disease-oriented toxicity predictive tool and integrating it with avail-able screening tools for better outcomes.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 3 (estimated)
- First submitted
- 27 Mar 2024
- Start date
- 15 Mar 2022
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- European Institute of Oncology
- Diseases
- Head and neck cancer
- NCT number
- NCT06344208
What you commit to
- Study type: Observational
- Planned participants: 3
- From 15 Mar 2022 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who received systemic treatments in the past for other primary tumors
Other illness
- Patient with cancer in other sites than HN \< than 2 years except for prostate cancer cT1-2, Gleason 3+3, NIMBC, initial Non Melanoma Skin Cancer, in situ cervical cancer)
Other
- PS ECOG 3-4
Who the study is looking for
- Patients aged ≥ 70 years
- Histological diagnosis of squamous cell or undifferentiated HNC in stage III-IV AJCC ed VIII (si-nonasal, nasopharynx, oral cavity, oropharynx, unknown primary with HPV pos, larynx and hy-popharynx) and candidated to curative non surgical treatment (radiotherapy alone, Chemora-diation with platinum salts; radiation+cetuximab)
- Evaluable disease accordingly to RECIST criteria 1.1
- Willing of sign a written informed consent
- Adequate organ function
Age in the registry: 70 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| European Institute of Oncology Coordinator of this site? Confirm its status | Milan | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.